Ibandronate

Drugs

Volumn 57, Issue 1, 1999, Pages 101-110

  Dooley, Mukta ^a   Balfour, Julia A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM ION; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PHOSPHATE; RISEDRONIC ACID; RPR 102289A; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; BONE DENSITY; BONE METASTASIS; BONE PAIN; BRONCHOSPASM; CALCIUM BLOOD LEVEL; CHILL; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG POTENCY; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; MYALGIA; NONHUMAN; ORAL DRUG ADMINISTRATION; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PAGET BONE DISEASE; POSTMENOPAUSE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BONE DENSITY; BONE NEOPLASMS; BONE RESORPTION; DIPHOSPHONATES; FEMALE; HUMANS; HYPERCALCEMIA; MALE; NEOPLASMS; OSTEITIS DEFORMANS; OSTEOPOROSIS, POSTMENOPAUSAL;

ANIMALIA;

EID: 0032893099     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957010-00011     Document Type: Review

References (23)

1. 1. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9 (5): 745-51
2. 2. Mühlbauer RC, Bauss F, Schenk R, et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991 Sep; 6: 1003-11
3. 45Ca kinetics in the intact rat. Osteoporos Int 1996; 6 (2): 166-70
4. 4. Monier-faugere MC, Friedler RM, Bauss F, et al. A new bisphosphonate, BM-21.0955, prevents hone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res 1993 Nov; 8 (11): 1345-55
5. 5. Yoneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastases of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997; 99: 2509-17
6. 6. Thiébaud D, Husl B, Jacquet AF, et al. Effects of ibandronate I.V. bolus injection in healthy men and postmenopausal women [abstract]. J Bone Miner Res 1997; 12 Suppl. 1: S343
7. 7. Green JR, Seltenmeyer Y, Jaeggi KA, et al. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol 1997; 80: 225-30
8. 8. Rizzoli R, Caverzasio J, Bauss F, et al. Inhibition of bone resorption by the bisphosphonate BM 21.0955 is not associated with an alteration of the renal handling of calcium in rats infused with parathyroid hormone-related protein. Bone 1992; 13: 321-5
9. 9. Boehringer Mannheim. European Public Assessment Report (EPAR). November 1996
10. 10. Neugebauer G, Hagena C, Sakalová A, et al. Pharmacokinetics of ibandronate, a highly potent antiresorptive drug on bone metabolism in patients with multiple myeloma [abstract]. Eur J Clin Pharmacol 1998; 54 (6): A18
11. 11. Boehringer Mannheim. Ibandronate in hypercalcemia of malignancy. Product Monograph, Data on File
12. 12. Wüster C, Schöter KH, Thiébaud D, et al. Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia. Bone Miner 1993; 22: 77-85
13. 13. Ralston SH, Thiebaud D, Herrmann Z, et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 1997; 75 (2): 295-300
14. 14. Pecherstorfer M, Herrmann Z, Body J-J, et al. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996 Jan; 14: 268-76
15. 15. Blind E, Raue F, Meinel T, et al. Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955. Horm Metab Res 1993 Jan; 25: 40-4
16. 16. Wnuk RS, Kokot F, Wiecek A. Influence of ibandronate therapy on intact parathormone (iPTH) concentration in hypercalcaemia of malignancy [abstract]. Nephrol Dial Transplant 1996; 11 (6): A37
17. 17. Pecherstorfer M, Ludwig H, Schlosser K, et al. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J Bone Miner Res 1996 May; 11 (5): 587-93
18. 18. Coleman RE, Purohit OP, Black C, et al. Ibandronate: a welltolerated new oral bisphosphonate for the treatment of bone metastases [abstract]. Breast 1995 Sep; 4: 236
19. 19. Thiébaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997; 103: 298-307
20. 20. Ravn P, Clemmesen B, Riis BJ, et al. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1 year, randomized, double-blind, placebo-controlled dose-finding study. Bone 1996; 19 (5): 527-33
21. 21. Grauer A, Knaus J, Seibel MJ, et al. Treatment of Paget's disease of bone with the new bisphosphonate BM 21.0955 by intravenous bolus injection [abstract]. J Bone Miner Res 1996; 11 Suppl. 1
22. 22. Grauer A, Heichel S, Knaus J, et al. Long term effects of ibandronate treatment in Paget's disease of bone [abstract]. J Bone Miner Res 1996; 11 Suppl. 1: S498
23. 23. Boehringer Mannheim. Bondronat product information. June 1996